Effective response to intravitreal faricimab in a patient with myopic neovascular membrane resistant to aflibercept
Article Sidebar
Main Article Content
Abstract
A 56-year-old woman with pathological myopia and macular neovascularization in the right eye was treated with 20 intravitreal injections of aflibercept following a treat-and-extend protocol, with no significant clinical improvement. A single intravitreal injection of faricimab was administered, after which the patient showed complete resolution of subretinal fluid and reduced neovascular lesions. Her visual acuity improved from 20/200 to 20/80 in the right eye, and she remained stable for 9 months without further signs of neovascular activity. Faricimab, which targets both VEGF-A and Ang-2, may be an effective alternative in myopic neovascular membranes resistant to aflibercept. Larger studies are needed to explore the long-term efficacy of faricimab in treating pathological myopia.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Ikuno Y, Ohno-Matsui K, Wong TY, et al; MYRROR Investigators. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR Study. Ophthalmology 2015;122:1220-27.
Korol AR, Zadorozhnyy OS, Naumenko VO, et al. Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study. Clin Ophthalmol 2016;10:2223-9.
Wang JK, Huang TL, Chang PY, et al. Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization. Sci Rep 2018;8:14389.
Zhang Z, Shen MM, Fu Y. Combination of AIBP, apoA-I, and aflibercept overcomes anti-VEGF resistance in neovascular AMD. Invest Ophthalmol Vis Sci 2022;63:2.
Hara C, Wakabayashi T, Toyama H, et al. Characteristics of patients with neovascular age-related macular degeneration who are non-responders to intravitreal aflibercept. Br J Ophthalmol 2018:bjophthalmol-2018-312275.
Agostini H, Abreu F, Baumal CR, et al. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes. Graefes Arch Clin Exp Ophthalmol 2024;262:3437-51.
Yen WT, Wu CS, Yang CH, et al. Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis. Sci Rep 2024;14:2485.
Nagai N, Suzuki M, Uchida A, et al. Non-responsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: implications of serous pigment epithelial detachment. Sci Rep 2016;6:29619.
Zhang Y, Han Q, Ru Y, Bo Q, Wei RH. Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application. Drug Des Devel Ther 2015;9:3413-21.
Ferro Desideri L, Traverso CE, Nicolò M, Munk MR. Faricimab for the treatment of diabetic macular edema and neovascular age-related macular degeneration. Pharmaceutics 2023;15:1413.